vatalanib

DRUG13 trials

Sponsors

Novartis Pharmaceuticals, Novartis, Alliance for Clinical Trials in Oncology, European Organisation for Research and Treatment of Cancer - EORTC, George Albert Fisher

Conditions

Brain and Central Nervous System TumorsColonic NeoplasmsColorectal NeoplasmsGastrinomaGastrointestinal Carcinoid TumorGlucagonomaInsulinomaIslet Cell Carcinoma

Phase 1

Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

CompletedNCT00128700

European Organisation for Research and Treatment of Cancer - EORTCBrain and Central Nervous System Tumors

Start: 2005-06-30Updated: 2012-09-24

Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer

CompletedNCT00185588

George Albert FisherPancreatic Cancer

Start: 2004-10-31End: 2009-12-31Updated: 2014-09-15

Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer

TerminatedNCT00293371

University of California, San FranciscoProstate Cancer

Start: 2005-02-28End: 2006-09-30Updated: 2012-10-11

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

CompletedNCT00387933

Duke UniversityBrain and Central Nervous System Tumors

Start: 2005-07-31Updated: 2015-10-14

Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors

CompletedNCT00390000

Mayo ClinicUnspecified Adult Solid Tumor, Protocol Specific

Start: 2007-01-25End: 2016-08-04Updated: 2019-04-08

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

CompletedNCT00655655

Mayo ClinicGastrinoma, Glucagonoma, Insulinoma +17

Start: 2004-12-31End: 2018-01-11Target: 96Updated: 2024-08-21

Phase 2

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes

CompletedNCT00072475

Alliance for Clinical Trials in OncologyLeukemia, Myelodysplastic/Myeloproliferative Neoplasms, Myelodysplastic Syndromes

Start: 2003-12-31End: 2014-06-30Updated: 2016-08-01

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

WithdrawnNCT00227773

Eastern Cooperative Oncology GroupGastrointestinal Carcinoid Tumor, Islet Cell Carcinoma

Updated: 2015-10-08

Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

CompletedNCT00348790

Northwestern UniversityBrain and Central Nervous System Tumors, Sarcoma

Start: 2006-05-31End: 2013-07-31Updated: 2018-10-26

Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery

CompletedNCT00563823

Cambridge University Hospitals NHS Foundation TrustMelanoma (Skin)

Start: 2006-02-28End: 2010-10-31Target: 34Updated: 2013-08-02

Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

CompletedNCT00590343

Louisiana State University Health Sciences Center in New OrleansMetastatic Neuroendocrine Tumors

Start: 2004-11-30End: 2010-10-31Updated: 2011-06-29

Phase 3

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

CompletedNCT00056459

NovartisColonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms

Start: 2003-02-28Updated: 2020-02-10

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

CompletedNCT00056446

Novartis PharmaceuticalsColonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms

Start: 2003-01-31End: 2007-01-31Updated: 2017-03-06

Related Papers

A rank-based randomized phase II design when the phase III design is based on overall survival (OS).

Journal of Clinical Oncology2014-05-20

Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

2011-04-04129 citations